scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone617-517-0730
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees21
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable
Scpharmaceuticals (NASDAQ:SCPH) Frequently Asked Questions
What is Scpharmaceuticals' stock symbol?
Scpharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH."
How were Scpharmaceuticals' earnings last quarter?
Scpharmaceuticals Inc (NASDAQ:SCPH) posted its earnings results on Wednesday, August, 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.49) by $0.10. View Scpharmaceuticals' Earnings History.
When is Scpharmaceuticals' next earnings date?
What price target have analysts set for SCPH?
3 Wall Street analysts have issued 1 year price targets for Scpharmaceuticals' shares. Their forecasts range from $5.00 to $13.00. On average, they expect Scpharmaceuticals' share price to reach $9.00 in the next year. This suggests a possible upside of 41.3% from the stock's current price. View Analyst Price Targets for Scpharmaceuticals.
What is the consensus analysts' recommendation for Scpharmaceuticals?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scpharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Scpharmaceuticals.
Has Scpharmaceuticals been receiving favorable news coverage?
News stories about SCPH stock have been trending positive on Wednesday, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Scpharmaceuticals earned a news impact score of 2.1 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Scpharmaceuticals.
Are investors shorting Scpharmaceuticals?
Scpharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totalling 58,800 shares, an increase of 17.4% from the August 30th total of 50,100 shares. Based on an average trading volume of 64,700 shares, the short-interest ratio is presently 0.9 days. Currently, 0.7% of the shares of the company are short sold. View Scpharmaceuticals' Current Options Chain.
Who are some of Scpharmaceuticals' key competitors?
Some companies that are related to Scpharmaceuticals include Intra-Cellular Therapies (ITCI), Urogen Pharma (URGN), Progenics Pharmaceuticals (PGNX), Lannett (LCI), Milestone Pharmaceuticals (MIST), BioDelivery Sciences International (BDSI), Synthorx (THOR), Beyondspring (BYSI), Evolus (EOLS), Crinetics Pharmaceuticals (CRNX), Collegium Pharmaceutical (COLL), Stemline Therapeutics (STML), Verrica Pharmaceuticals (VRCA), Magenta Therapeutics (MGTA) and Avedro (AVDR).
What other stocks do shareholders of Scpharmaceuticals own?
Who are Scpharmaceuticals' key executives?
Scpharmaceuticals' management team includes the folowing people:
- Mr. John H. Tucker, Pres, CEO, CFO & Director (Age 56)
- Dr. Pieter Muntendam, Consultant (Age 61)
- Ms. Rachael Nokes, Principal Accounting Officer
- Katherine Taudvin, Director of Corp. Devel. & Investor Relations
- Dr. John Mohr Pharm.D., Sr. VP of Clinical Devel. & Medical Affairs
When did Scpharmaceuticals IPO?
(SCPH) raised $96 million in an IPO on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.
How do I buy shares of Scpharmaceuticals?
Shares of SCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Scpharmaceuticals' stock price today?
One share of SCPH stock can currently be purchased for approximately $6.37.
How big of a company is Scpharmaceuticals?
Scpharmaceuticals has a market capitalization of $118.35 million. The company earns $-29,440,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Scpharmaceuticals employs 21 workers across the globe.View Additional Information About Scpharmaceuticals.
What is Scpharmaceuticals' official website?
How can I contact Scpharmaceuticals?
Scpharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The company can be reached via phone at 617-517-0730 or via email at [email protected]
MarketBeat Community Rating for Scpharmaceuticals (NASDAQ SCPH)
MarketBeat's community ratings are surveys of what our community members think about Scpharmaceuticals and other stocks. Vote "Outperform" if you believe SCPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
